Media Coverage

Quest Diagnostics is partnering with Mood Media to introduce "Quest TV," a curated, video programming network that is pre-recorded, with short-form and family-friendly content. The rollout includes more than 2,200 Quest Diagnostics waiting room lobbies in patient service centers across the U.S. "Live TV means potential for inappropriate programming, unsettling news segments or advertisements, and more," says Chris Grant, executive director of patient services, Quest Diagnostics. "Ultimately, this means we can feel confident in the type of experience and ambiance we’re setting for our waiting patients."

True innovators go to great lengths to change the world around them, says Jake Orville, general manager at Cleveland HeartLab, a CardioMetabolic and Endo franchise at Quest Diagnostics. “You can be known as innovative, but to be disruptive in your innovation, you have to do more than move the needle,” Orville says. “To get recognized as a leader and to gain momentum in your innovation, you have to have exponential growth and make a big impact.” Orville and his team took aim at heart disease, the nation’s leading killer of both men and women. In his view, nothing else comes close to it both in terms of clinical need and the opportunity to make a profound impact — the inflammation testing that CHL has developed could eliminate billions in health care costs.

Quest Diagnostics Inc. on Tuesday reported third-quarter earnings of $213 million. On a per-share basis, the Secaucus, New Jersey-based company said it had net income of $1.53. Earnings, adjusted for one-time gains and costs, were $1.68 per share. The results met Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was also for earnings of $1.68 per share. The medical laboratory operator posted revenue of $1.89 billion in the period, which fell short of Street forecasts. Eight analysts surveyed by Zacks expected $1.95 billion.

Quest Diagnostics, the world's leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, November 29, 2018 at The InterContinental New York Times Square Hotel at 300 W. 44th St.

Quest Diagnostics today reported 2 percent year-over-year revenue growth for the third quarter missing analyst expectations. Revenue was $1.89 billion for the three- month period ended Sept. 30, 2018, up from $1.86 billion in the third quarter last year. The consensus Wall Street estimate was $1.95 billion. Ross Muken, analyst with investment bank Evercore ISI called the quarter "mediocre to modestly disappointing," in a note to investors. He cited the missed revenues, and the continuation of headwinds that the company faced last quarter as some of the reasons for his modest disappointment.